These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8497347)

  • 61. Clinical and epidemiologic aspects of oral contraceptive safety.
    Schrogie JJ
    Semin Drug Treat; 1973; 3(2):143-56. PubMed ID: 4584284
    [No Abstract]   [Full Text] [Related]  

  • 62. [Synthesis of gestodene].
    Hofmeister H; Annen K; Laurent H; Petzoldt K; Wiechert R
    Arzneimittelforschung; 1986 May; 36(5):781-3. PubMed ID: 3730011
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety of modern oral contraceptives.
    Henzl MR
    Lancet; 1996 Jan; 347(8996):257-8. PubMed ID: 8551892
    [No Abstract]   [Full Text] [Related]  

  • 64. Safety of modern oral contraceptives. The International Committee for Research in Reproduction.
    Johannisson E
    Lancet; 1996 Jan; 347(8996):258. PubMed ID: 8551893
    [No Abstract]   [Full Text] [Related]  

  • 65. Fatal pulmonary embolus in a patient treated with Marvelon.
    Scolding NJ; Gibby OM
    J R Coll Gen Pract; 1988 Dec; 38(317):568. PubMed ID: 2978521
    [No Abstract]   [Full Text] [Related]  

  • 66. [Desogestrel - a new progestin].
    Presl J
    Cesk Gynekol; 1983 Jun; 48(5):382-3. PubMed ID: 6225541
    [No Abstract]   [Full Text] [Related]  

  • 67. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations.
    Wilde MI; Balfour JA
    Drugs; 1995 Aug; 50(2):364-95. PubMed ID: 8521763
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Trends and Factors Associated with Oral Contraceptive Use among Korean Women.
    Park H; Kim K
    Healthcare (Basel); 2021 Oct; 9(10):. PubMed ID: 34683066
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adult-onset acne: prevalence, impact, and management challenges.
    Rocha MA; Bagatin E
    Clin Cosmet Investig Dermatol; 2018; 11():59-69. PubMed ID: 29440921
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Oily Skin: A review of Treatment Options.
    Endly DC; Miller RA
    J Clin Aesthet Dermatol; 2017 Aug; 10(8):49-55. PubMed ID: 28979664
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Amelioration of lipid abnormalities by vitamin therapy in women using oral contraceptives.
    Torkzahrani S; Heidari A; Mostafavi-Pour Z; Ahmadi M; Zal F
    Clin Exp Reprod Med; 2014 Mar; 41(1):15-20. PubMed ID: 24693493
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice.
    Pushparajah DS; Röhm P; Höschen K; Albers D; Nowack C
    Clin Drug Investig; 2011; 31(2):121-34. PubMed ID: 21155614
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg.
    Krishnan S; Kiley J
    Int J Womens Health; 2010 Aug; 2():235-9. PubMed ID: 21151728
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of injectable and oral contraceptives on serum lipids.
    Berenson AB; Rahman M; Wilkinson G
    Obstet Gynecol; 2009 Oct; 114(4):786-794. PubMed ID: 19888036
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of extended and continuous use oral contraceptives.
    Wright KP; Johnson JV
    Ther Clin Risk Manag; 2008 Oct; 4(5):905-11. PubMed ID: 19209272
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hormonal contraception in adolescents: special considerations.
    Ornstein RM; Fisher MM
    Paediatr Drugs; 2006; 8(1):25-45. PubMed ID: 16494510
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effectiveness and acceptability of progestogens in combined oral contraceptives - a systematic review.
    Kulier R; Helmerhorst FM; Maitra N; Gülmezoglu AM
    Reprod Health; 2004 Jun; 1(1):1. PubMed ID: 15357865
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels.
    Mantel-Teeuwisse AK; Kloosterman JM; Maitland-van der Zee AH; Klungel OH; Porsius AJ; de Boer A
    Drug Saf; 2001; 24(6):443-56. PubMed ID: 11368251
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.
    Godsland IF; Winkler U; Lidegaard O; Crook D
    Drugs; 2000 Oct; 60(4):721-869. PubMed ID: 11085198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.